

Efficacy #274

Please type a plus sign (+) inside this box - PTO/SB/08-00
Approved for use through 10/31/2002. OMB No. 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|------------------------|------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 09/101,518 |
| | | | | Filing Date | January 11, 1996 |
| | | | | First Named Inventor | Li |
| | | | | Group Art Unit | 1646 |
| | | | | Examiner Name | Pak, M. |
| Sheet | 1 | of | 1 | Attorney Docket Number | PF218US |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|----------|----------------------|---|--|---|
| Examiner Initials | Cite No. | U.S. Patent Document | | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Kind Code: | Name of Patentee or Applicant of Cited Document | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|---|------------------------|--|---|
| Examiner Initials | Cite No. | Foreign Patent Document | | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Office ³ Number ⁴ | Kind Code ⁵ | | |
| | | | | | |

| OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS | | | | | |
|--|----------|--|--|--|--|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | |
| MOP | CK | R&D SYSTEMS TECHNICAL DATA SHEET, "Monoclonal Anti-Human CXCR3 Antibody," Catalog Number MAB160, December 2002 | | | |
| ↑ | CL | BD PHARMINGEN TECHNICAL DATA SHEET, "CD183 (CXCR3) Purified Mouse Anti-Human Monoclonal Antibody," Catalog Number 337183, March 2002 | | | |
| | CM | QIN et al., "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions," J. Clin. Invest. 101(4):746-753 (1998). | | | |
| | CN | GARCIA-LÓPEZ et al., "CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells," Lab. Invest. 81(3):409-418 (2001) | | | |
| ↓ MOP | CO | JINQUAN et al., "CXCR3 expression and activation of eosinophils: role of IFN-γ-Inducible Protein 10 and Monokine Induced by IFN-γ," J. Immunol. 165:1548-1556 (2000). | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | | | |
|--------------------|-------------|-----------------|---------|
| Examiner Signature | MICHAEL YAK | Date Considered | 5-30-03 |
|--------------------|-------------|-----------------|---------|

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.

² Unique citation designation number. See annexed Kinds of U.S. Patent Documents. ³ Enter Office that issues the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.10, if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.